Exhibit 15.1



































Management Discussion
and Analysis



December 31, 2016

























MANAGEMENT’S DISCUSSION
AND ANALYSIS



March 28, 2017







This management’s discussion and analysis
of Aptose Biosciences Inc. (“Aptose”, the “Company”, “we”, “our”, “us”
and similar expressions) should be read in conjunction with the Company’s annual audited financial statements for the year
ended December 31, 2016 and the annual report on form 20-F of the Company for the year ended December 31, 2016 which can be found
on SEDAR at www.sedar.com andEDGAR at www.sec.gov/edgar.shtml.





CAUTION
REGARDING FORWARD-LOOKING STATEMENTS



This management’s discussion and analysis
may contain forward-looking statements within the meaning of securities laws. Such statements include, but are not limited to,
statements relating to:



|· |  | our ability to obtain the substantial capital we require to fund research and operations;
|- |  | -----------------------------------------------------------------------------------------

|· |  | our business strategy;
|- |  | ----------------------

|· |  | our clinical development plans;
|- |  | -------------------------------

|· |  | our plans to secure strategic partnerships to assist in the further development
of our product candidates and to build our pipeline;
|- |  | ------------------------------------------------------------------------------------------------------------------------------------

|· |  | our plans to conduct clinical trials and preclinical programs;
|- |  | --------------------------------------------------------------

|· |  | our reliance on external contract research/manufacturing organizations for certain
activities;
|- |  | ----------------------------------------------------------------------------------------------

|· |  | potential exposure to legal actions and potential need to take action against other
entities.
|- |  | ---------------------------------------------------------------------------------------------

|· |  | our expectations regarding the progress and the successful and timely completion
of the various stages of our drug discovery, preclinical and clinical studies and the regulatory approval process;
|- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|· |  | our plans, objectives, expectations and intentions; and
|- |  | -------------------------------------------------------

|· |  | other statements including words such as “anticipate”, “contemplate”,
“continue”, “believe”, “plan”, “estimate”, “expect”, “intend”,
“will”, “should”, “may”, and other similar expressions.
|- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



The forward-looking statements reflect our
current views with respect to future events, are subject to significant risks and uncertainties, and are based upon a number of
estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements
to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking
statements, including, among others:



|· |  | our ability to obtain the substantial capital we require to fund research and operations;
|- |  | -----------------------------------------------------------------------------------------

|· |  | our lack of product revenues and history of operating losses;
|- |  | -------------------------------------------------------------

|· |  | our early stage of development, particularly the inherent risks and uncertainties
associated with (i) developing new drug candidates generally, (ii) demonstrating the safety and efficacy of these drug candidates
in clinical studies in humans, and (iii) obtaining regulatory approval to commercialize these drug candidates;
|- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|· |  | our drug candidates require time-consuming and costly preclinical and clinical
testing and regulatory approvals before commercialization;
|- |  | -----------------------------------------------------------------------------------------------------------------------------------------

|· |  | clinical studies and regulatory approvals of our drug candidates are subject to
delays, and may not be completed or granted on expected timetables, if at all, and such delays may increase our costs and could
delay our ability to generate revenue;
|- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|· |  | our reliance on external contract research/manufacturing organizations for certain
activities;
|- |  | ----------------------------------------------------------------------------------------------

|· |  | potential exposure to legal actions and potential need to take action against other
entities;
|- |  | ---------------------------------------------------------------------------------------------

|· |  | the regulatory approval process;
|- |  | --------------------------------

|· |  | our ability to recruit patients for clinical trials;
|- |  | ----------------------------------------------------

|· |  | the progress of our clinical trials;
|- |  | ------------------------------------

|· |  | our ability to find and enter into agreements with potential partners;
|- |  | ----------------------------------------------------------------------

|· |  | our ability to attract and retain key personnel;
|- |  | ------------------------------------------------

|· |  | our ability to obtain and maintain patent protection;
|- |  | -----------------------------------------------------

|· |  | our ability to protect our intellectual property rights and not infringe on the
intellectual property rights of others;
|- |  | -----------------------------------------------------------------------------------------------------------------------

|· |  | our ability to comply with applicable governmental regulations and standards;
|- |  | -----------------------------------------------------------------------------

|· |  | development or commercialization of similar products by our competitors, many of
which are more established and have or have access to greater financial resources than us;
|- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|· |  | commercialization limitations imposed by intellectual property rights owned or
controlled by third parties;
|- |  | -----------------------------------------------------------------------------------------------------------

|· |  | potential product liability and other claims;
|- |  | ---------------------------------------------

|· |  | our ability to maintain adequate insurance at acceptable costs;
|- |  | ---------------------------------------------------------------

|· |  | further equity financing, which may substantially dilute the interests of our existing
shareholders;
|- |  | ----------------------------------------------------------------------------------------------------

|· |  | changing market conditions; and
|- |  | -------------------------------

|· |  | other risks detailed from time-to-time in our on-going quarterly filings, annual
information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and
Exchange Commission, and those which are discussed under the heading “Risk Factors” in this document.
|- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Should one or more of these
risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” underlying
those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking
statements are made as of the date of this management’s discussion and analysis or, in the case of documents incorporated
by reference herein, as of the date of such documents, and we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual
results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.





2




corporate
update



The following items highlight our
corporate activities during the year ended December 31, 2016 and any subsequent development up until the date hereof.



program
updates



APTO-253



Phase
Ib Trial



APTO-253 is being evaluated by Aptose in a Phase 1b clinical trial
in patients with relapsed / refractory hematologic malignancies.  For the study, a modified dose schedule was selected, such
that APTO-253 is being administered on the first two days of each 7-day dosing period of a 28-day cycle (i.e., days 1, 2, 8, 9,
15, 16, 22, 23). This resulted in lower per-administration dose levels to provide the same overall exposure per cycle achieved
in the prior Phase 1 solid tumor study, and to more consistently achieve the minimum exposure levels at the end of each dosing
period that may be important for efficacy.



The Phase 1b study was originally designed for approximately 15
patients to be enrolled in each of two arms of the dose escalation phase of the study: arm (A) was to include patients with acute
leukemias (including acute myeloid leukemia (“AML”)) and high-risk myelodysplastic syndromes (“MDS”); arm
(B) was to include patients with lymphomas (Hodgkin’s and non-Hodgkin’s Lymphoma) and multiple myeloma, followed by
enrollment of an additional fifteen (15) patients in each of two separate disease-specific expansion cohorts, for a total estimated
enrollment of 60 patients.



Aptose modified the clinical trial design for the Phase 1b study,
pending submission and review from regulatory authorities (Institutional Review Boards (“IRB”) & the Food and Drug
Administration (“FDA”), in order to focus all resources on the patient population most likely to benefit from APTO-253.
 Under the proposed modification, arm B of the dose-escalation phase of the study, as described above, will be discontinued.
 Arm A of the study, focused on patients with acute leukemias (particularly AML) and MDS remains unchanged.



Upon completion of the dose-escalation stage of the study and determination
of the appropriate dose, the study would enroll hematologic cancer indications selected from the groups that will be studied in
the dose-escalation phase, for enrollment in up to two planned disease-specific single-agent expansion cohorts.



For future development, upon selection of a lead hematologic indication
from this Phase 1b study, combination of APTO-253 with a standard therapy would be considered.



Clinical Hold and Current Status

We announced in November 2015 that the FDA,
following a voluntary suspension of dosing by Aptose and discussions with us, placed our Phase Ib clinical trial of APTO-253 in
patients with hematologic cancers on clinical hold. This hold was intended to evaluate the administration methods within the trial
and to ensure manufacturing and dosing procedures are consistent with FDA guidance and the Code of Federal Regulations.



The voluntary suspension of dosing by Aptose,
followed by a clinical hold by the FDA, was initiated to evaluate manufacturing processes and procedures upon the report of an
operational difficulty with an IV infusion pump at a clinical site. During dosing of a patient with 100 mg/m2 dose,
the clinical site experienced an infusion pump stoppage, caused by backflow pressure as a result of clogging of the in-line filter
used during the infusion. A safety review of the relevant safety data had been completed prior to initial discovery of the manufacturing
irregularities, and there have been no drug-related serious adverse events (“SAEs”) reported. The observed pharmacokinetic
levels in the patients treated were within the expected range. Thus, the clinical hold is based solely on the operation of the
administration of the subject infusion at the clinical site which is related to a product chemistry issue and has not shown to
be related to safety, efficacy or pharmacokinetic profile of the molecule.



We have worked with a chemistry-focused
Contract Manufacturing Organization (“CMO”) and determined that the root cause of the filter clogging event with the
prior drug product was chemistry-based. Likewise, we guided a qualified CMO to introduce new methodologies to formulate APTO-253
into a drug product that is safe and stable, and which should not result in filter clogging events in the future. Good Manufacturing
Practice (“GMP”) batches of the Active Pharmaceutical Ingredient (“API”) have been manufactured to provide
material for formulation studies and to supply the clinical drug product into the future. Based on numerous formulation studies
conducted by a CMO with expertise in formulation development, a new soluble and stable formulation for the drug product has been
selected. In parallel with these studies, mock infusion studies using the newly formulated prototype drug product demonstrated
no filter clogging, and supplementary mock infusion studies were performed at multiple CROs to ensure the durability and solubility
of the new formulation to be used in the infusion process/filter clogging that caused the clinical hold. In order to respond to
the FDA’s inquiry on the filter clogging issue which could result in the clinical hold being removed, Aptose must articulate
the root cause of the filter clogging incident to the FDA and demonstrate to the FDA that a newly manufactured batch of GMP-grade
APTO-253 drug substance and drug product has been formulated and should not cause such incidents in the future. On September 12,
2016, we submitted a formal response to the FDA regarding the clinical hold of our Phase 1b clinical trial of APTO-253 in patients
with hematologic cancers.





3




On October 12, 2016, we received a response
from the FDA informing us that the clinical hold would remain in place until Aptose provides to the FDA the standard chemistry,
manufacturing and control (“CMC”) information on the final GMP drug substance and drug product that will be manufactured
for the clinic. Data provided to the FDA in our response to the clinical hold questions were collected using prototype batches
of API and drug product. As the drug substance was changed from a salt to a free base, and the proportions of the original excipients
were modified in the drug product formulation, the FDA has requested additional information on the GMP-grade drug substance and
drug product that is will be manufactured for use in the clinic prior to making a decision on the hold and approval for the re-initiation
of the clinical trial.



We believe we have now developed a drug
product that does not cause filter clogging or pump stoppage during simulated infusion studies. The new formulation of APTO-253
offers the potential for improved handling characteristics for administration by infusion and the potential for creating new intellectual
property. However there can be no assurance that the FDA will remove the clinical, hold which could cause additional development
costs to the Company.



On December 29, 2016, we announced that
we had successfully manufactured multiple non-GMP batches of a new drug product formulation for APTO-253, including a batch that
had been stable and soluble for over six months. However, we also announced that we would have to repeat the production of the
fourth batch, a 40L batch that was the intended clinical supply because of a potential engineering design incompatibility that
occurred during the filling process. At that time, we believed that the root cause of the drug product stability failure and a
corrective action (“CAPA”) could be determined rapidly and that another manufacturing campaign to produce a GMP grade
clinical supply could be initiated in January 2017.



On January 23, 2017, we announced that
the root cause and CAPA studies would take longer than originally expected and that we would temporarily delay clinical activities
with APTO-253 in order to elucidate the cause of recent manufacturing setbacks related to the intravenous formulation of APTO-253
with the intention of restoring the molecule to a state supporting clinical development and partnering.



CG’806

In June 2016, Aptose announced a definitive agreement with South
Korean company CrystalGenomics, Inc. (“CG”), granting Aptose an exclusive option to research, develop and commercialize
CG026806 (“CG’806”) in all countries of the world except Korea and China, for all fields of use. CG’806
is a highly potent, non-covalent small molecule therapeutic agent. This multi-kinase inhibitor exhibits a picomolar IC50 toward
the FMS-like tyrosine kinase 3 with the Internal Tandem Duplication (“FLT3-ITD”) and potency against a host of mutant
forms of FLT3, as well as single-digit nanomolar IC50’s against Bruton’s tyrosine kinase (“BTK”) and its
C481S mutant (“BTK-C481S”). Further, CG’806 is a multi-targeted BTK / FLT3-ITD inhibitor, as it impacts other
relevant oncogenic targets, including the Aurora kinases (AURK), RET, MET, DDR2, and SRC kinases.



Aptose paid US$1.0 million (CA$1.294 million) (the “Option
Grant Fee”) to CG to acquire the option. Should we elect to exercise the option prior to the earlier of (i) filing of an
Investigational New Drug (“IND”) application with the FDA, (ii) first dosage of a human in a clinical trial, (iii)
payment of the Option Exercise Fee or (iii) twenty-four (24) months after the payment of the Option Grant Fee, we would pay an
additional US$2.0 million (the “Option Exercise Fee”) in cash or combination of cash and common shares, and would receive
full development and commercial rights for the program in all territories outside of the Republic of Korea and China. The agreement
can only be terminated by Aptose without cause or by both parties in the event of a material breach.



As a potent inhibitor of FLT3-ITD, CG’806
may become an effective therapy in this subset of AML patients, as the FLT3-ITD mutation occurs in approximately 30% of patients
with AML. Importantly, CG’806 targets other oncogenic kinases which may also be operative in FLT3-ITD AML, including RET
and SRC family kinases, thereby potentially allowing the agent to become an important therapeutic option for this difficult-to-treat
patient population.



The C481S mutation of BTK arises from therapy
with covalent, irreversible BTK inhibitors that target the active site Cysteine (“Cys”) residue of BTK, thereby conferring
resistance to other covalent BTK inhibitors. As a non-covalent, reversible inhibitor, CG’806 does not rely on the Cysteine
481 residue for inhibition of the BTK enzyme. Consequently, patients relapsed, refractory or intolerant to other commercially approved
or development stage BTK inhibitors with chronic lymphocytic leukemia (“CLL”) or mantle cell lymphoma (“MCL”)
may continue to be sensitive to CG’806 therapy.



CG’806
is currently in route scouting studies to select an appropriate synthetic pathway to manufacture the molecule, in formulation development
studies, and in various preclinical biological pathway and animal efficacy studies. Provided the studies continue on the anticipated
timeline, Aptose expects to file an IND application for a first-in-human clinical trial in late 2017 or early 2018. CG’806
is being developed with the intent to deliver the agent as a once-daily, oral therapeutic.





4




Multi-Targeting
Bromodomain Program

In November 2015, Aptose entered into a definitive agreement with
Moffitt Cancer Center for exclusive global rights to potent, dual-targeting, single-agent inhibitors for the treatment of hematologic
and solid tumor cancers. These small molecule agents are highly differentiated inhibitors of the Bromodomain and Extra-Terminal
motif (“BET”) protein family members, which simultaneously target specific kinase enzymes. The molecules developed
by Moffitt were reported to exhibit potency against the BET family members, including bromodomain 4 (“BRD4”), and specific
oncogenic kinases which, when inhibited, are synergistic with BET inhibition. Under the agreement, Aptose has access to the drug
candidates developed by Moffitt and the underlying intellectual property covering certain chemical modifications enabling bromodomain
(“BRD”) inhibition on the chemical backbone of a kinase inhibitor.



In January 2017, Aptose terminated the collaboration with Moffitt
Cancer Center for the development of the dual BRD4 / JAK2 inhibitor program.



Multi-Targeting
Epigenetic Program

In November 2015, Aptose also announced an exclusive drug discovery
partnership with Laxai Avanti Life Sciences (“LALS”) for the development of next generation epigenetic-based therapies.
Under the agreement, LALS is responsible for optimizing candidates derived from Aptose's relationship with the Moffitt Cancer
Center. Aptose will own global rights to all newly discovered candidates characterized and optimized under the collaboration,
including all generated intellectual property. As of November 2016, Aptose and LALS have generated novel compounds that inhibit
both the bromodomain proteins and oncogenic kinases, while improving pharmaceutical properties that could serve as a basis for
further optimization towards a lead preclinical candidate. However, due to a prioritization of development efforts, Aptose and
LALS have suspended work on the program, and the collaboration with LALS has been terminated. However, the program delivered novel
IP and hit molecules for further optimization. As a consequence, Aptose may choose to out-license the program.



financing
activities



At-The-Market (“ATM”) Facility



On April 2, 2015, Aptose entered into an at-the-market equity facility
(“ATM Facility”) with Cowen and Company, LLC, acting as sole agent. Under the terms of this facility, Aptose may, from
time to time, sell common shares having an aggregate offering value of up to US$20 million through Cowan and Company, LLC. The
Company determines, at its sole discretion, the timing and number of shares to be sold under the ATM Facility.



During the year ended December 31, 2016, the Company issued 3,673,933
common shares through the ATM raising net proceeds of USD$5.69 million or CDN$7.55 million. Costs associated with the proceeds
included a 3% cash commission as well as legal and accounting fees.



Subsequent to the year end, we issued an additional 3,127,836common shares under the ATM Facility for gross proceeds of US$3.707 million.



April 2014

In April 2014, we completed a public offering of common shares.
Aptose issued 4,708,334 (56,500,000 pre-consolidation) common shares at a purchase price of $6.00 ($0.50 pre-consolidation) per
common share, including 541,667 (6,500,000 pre-consolidation) common shares pursuant to the partial exercise of an over-allotment
option, for aggregate gross proceeds of $28.3 million. The total costs associated with the transaction were approximately $2.7
million which includes a cash commission of $2.0 million based on 7% of the gross proceeds received as part of the offering.



December 2013

In December 2013, Aptose completed a public offering of common shares.
Aptose issued 1,060,833 (pre-consolidation 12,730,000) common shares at a price of $6.60 (pre-consolidation $0.55) per common share
and an additional 159,125 (pre-consolidation 1,909,500) common shares upon the exercise of the overallotment option for aggregate
gross proceeds of $8.1 million.



The total costs associated with the transaction were approximately
$1.1 million which include a cash commission of $483 thousand based on 6% of the gross proceeds received as part of the offering,
and the issuance of 73,198 (pre-consolidation 878,370) broker warrants with an estimated fair value of $350 thousand. The fair
value of these warrants was determined using the Black Scholes model with a 24 month time to maturity, an assumed volatility of
130% and a risk free interest rate of 1.5%. Each broker warrant was exercisable into one common share of the Company at a price
of $6.60 (pre-consolidation $0.55) for a period of twenty four months following closing of the offering.





5




warrant
exercises



During the year ended December 31, 2015, 81,000 Common Share purchase
warrants were exercised for proceeds of $348,000. During the seven months ended December 31, 2014, 1,231,000 Common Share purchase
warrants were exercised for proceeds of $6,648,000. During the year ended December 31, 2016 the remaining warrants from a 2011
financing expired. As at December 31, 2016 there are no outstanding warrants.



LIQUIDITY
AND CAPITAL RESOURCES



Since its inception, Aptose has financed its operations and technology
acquisitions primarily from equity and debt financing, proceeds from the exercise of warrants and stock options, and interest income
on funds held for future investment.



We currently do not earn any revenues from our drug candidates and
are therefore considered to be in the development stage. The continuation of our research and development activities and the commercialization
of the targeted therapeutic products are dependent upon our ability to successfully finance and complete our research and development
programs through a combination of equity financing and payments from strategic partners. We have no current sources of significant
payments from strategic partners.



In managing its liquidity risk, the Company has considered its available
cash and cash equivalents and has reprioritized its resources towards the development of CG 806. This reprioritization has resulted
in reduced expected cash outflows for the year ending December 31, 2017 relative to what was forecast as of September 30, 2016.
The Company has also considered additional cash raised through its At-The-Market (“ATM”) facility of $US 3.7M since
December 31, 2016 and its ability to continue to raise funds under this facility in 2017 in assessing whether it will have sufficient
resources to fund research and development operations through to at least the year ending December 31, 2017.



After considering the above factors, management have concluded
that there are no material uncertainties related to events or conditions that may cast substantial doubt upon the Company’s
ability to continue as a going concern. However, the estimates made by management in reaching this conclusion are based on information
available as of the date this report was authorized for issuance. Accordingly, actual experience will differ from those estimates
and the variation may be material.



Cash
Position



At December 31, 2016, we had cash and cash equivalents of $10.7
million compared to cash and cash equivalents and investments of $19.7 million at December 31, 2015. We generally invest our cash
in excess of current operational requirements in highly rated and liquid instruments. Investment decisions are made in accordance
with an established investment policy administered by senior management and overseen by our Audit Committee and Board of Directors.
As at December 31, 2016, our cash and cash equivalents consisted of cash of $3.9 million (December 31, 2015 - $761 thousand) and
in funds deposited into high interest savings accounts in both Canadian and US funds totaling $6.7 million (December 31, 2015 -
$10.7 million). Working capital (representing primarily cash, cash equivalents, investments and other current assets less current
liabilities) at December 31, 2016 was $9.6 million (December 31, 2015 –$18.5 million). Total assets as of December 31, 2016
total $11.6 million (December 31, 2015 - $21.2 million).



We do not expect to generate positive cash flow from operations
for the foreseeable future due to additional research and development costs, including costs related to drug discovery, preclinical
testing, clinical trials, manufacturing costs and operating expenses associated with supporting these activities. It is expected
that negative cash flow will continue until such time, if ever, that we receive regulatory approval to commercialize any of our
products under development and/or royalty or milestone revenue from any such products exceeds expenses.



RESULTS
OF OPERATIONS



Our net loss for the year ended December 31, 2016 was $18.6 million
($1.46 per share) compared with $14.6 million ($1.23 per share) during the year ended December 31, 2015 and with a loss of $7.8
million ($0.67 per share) in the seven months ended December 31, 2014.



The increase in net loss during the year ended December 31, 2016
compared with the year ended December 31, 2015 is primarily due to higher research and development activities related to the $1.294
million option fee for CG’806, costs associated with APTO-253 and the new Moffitt/LALS program as well as additional headcount
in the research and clinical departments to support these activities. In addition, the lower Canadian dollar resulted in an increase
in our US dollar denominated costs in comparison with the prior year. Additionally, we recognized net finance income of $1.5 million
in the prior year period mostly due to gains on our US dollar denominated cash and cash equivalents compared with a net finance
income of $39 thousand in the current year period due to interest income net of foreign exchange losses on our US dollar denominated
cash and cash equivalents.



The increase in net loss and comprehensive loss in the year ended
December 31, 2015 compared with the seven months ended December 31, 2014 is due to a twelve month period compared with a seven
month period as well as increased research and development costs associated with the APTO-253 Phase Ib clinical trial described
above for which the first patient was enrolled in January 2015. The increased research and development costs were offset by a higher
finance income related to foreign currency gains on our USD cash and cash equivalents balances due to the devaluation of the Canadian
dollar.





6




We utilized cash of$16.4
million in our operating activities in the year ended December 31, 2016 compared with $12.7 million
in the year ended December 31, 2015 and $6.7 million in the seven months ended December 31, 2014. The increase in cash utilized
in the current year is predominantly due to increased research and development activities



At December 31, 2016, we had cash and cash equivalents of $10.7
million compared to cash and cash equivalents and investments of $19.7 million at December 31, 2015.



SELECTED
ANNUAL FINANCIAL DATA



The following selected consolidated financial data have been derived
from, and should be read in conjunction with, the accompanying audited consolidated financial statements for the year ended December
31, 2016 (the “Financial Statements”) which are prepared in accordance with International Financial Reporting
Standards (“IFRS”) as issued by the International Accounting Standards Board.



|Consolidated Statements of Loss and Comprehensive Loss           |  | Year ended December 31, |        |   | Year ended  December 31, |   |        | 7 months ended  December 31 | 
|---------------------------------------------------------------- |  | ----------------------- | ------ | - | ------------------------ | - | ------ | --------------------------- | 
|(amounts in Canadian thousands except for per common share data) |  | 2016                    |        |   | 2015                     |   |        | 2014                        | 
|REVENUE                                                          |  | $                       | —      |   |                          | $ | —      |                             | 
|                                                                 |  |                         |        |   |                          |   |        |                             | 
|EXPENSES                                                         |  |                         |        |   |                          |   |        |                             | 
|Research and development                                         |  |                         | 10,322 |   |                          |   | 6,254  |                             | 
|General and administrative                                       |  |                         | 8,344  |   |                          |   | 9,845  |                             | 
|Operating expenses                                               |  |                         | 18,666 |   |                          |   | 16,099 |                             | 
|Finance expense                                                  |  |                         | 66     |   |                          |   | 43     |                             | 
|Finance income                                                   |  |                         | (105   | ) |                          |   | (1,516 | )                           | 
|Net finance expense (income)                                     |  |                         | (39    | ) |                          |   | (1,473 | )                           | 
|Net loss and total comprehensive loss for the period             |  |                         | 18,627 |   |                          |   | 14,626 |                             | 
|Basic and diluted loss per common share                          |  | $                       | 1.46   |   |                          | $ | 1.23   |                             | 
|Weighted average number of common shares                         |  |                         |        |   |                          |   |        |                             | 
|outstanding used in the calculation of:                          |  |                         |        |   |                          |   |        |                             | 
|Basic and diluted loss per share                                 |  |                         | 12,743 |   |                          |   | 11,906 |                             | 
|Total Assets                                                     |  |                         | 11,610 |   |                          | $ | 21,249 |                             | 
|Total Long-term liabilities                                      |  | $                       | —      |   |                          | $ | —      |                             | 





7




Research
and Development

Research and development expenses totaled $10.3 million in the year
ended December 31, 2016 compared with $6.3 million in the year ended December 31, 2015 and totaled $2.4 million for the seven months
ended December 31, 2014. Research and development costs consist of the following:



Components of research and development expenses:

|                                |  |              |        |  |              |   |       |                | 
|------------------------------- |  | ------------ | ------ |  | ------------ | - | ----- | -------------- | 
|                                |  | Year ended   |        |  | Year ended   |   |       | 7 months ended | 
|                                |  | December 31, |        |  | December 31, |   |       | December 31,   | 
|                                |  | 2016         |        |  | 2015         |   |       | 2014           | 
|                                |  |              |        |  |              |   |       |                | 
|Research and Development costs  |  | $            | 6,442  |  |              | $ | 4,046 |                | 
|Crystal Genomics Option Fee (a) |  |              | 1,294  |  |              |   | -     |                | 
|Salaries                        |  |              | 2,246  |  |              |   | 1,969 |                | 
|Stock-based compensation        |  |              | 293    |  |              |   | 210   |                | 
|Depreciation of equipment       |  |              | 47     |  |              |   | 29    |                | 
|                                |  | $            | 10,322 |  |              | $ | 6,254 |                | 



Expenditures for the year ended December 31, 2016 increased significantly over the year
ended December 31, 2015 due to the following reasons:



| | · | Research and development activities related to the option fee for CG’806;
| | - | -------------------------------------------------------------------------

| | · | Costs associated with the LALS/Moffitt collaboration developing epigenetic single molecule inhibitors
of multiple targets, including the BET proteins, and other kinases for which no comparable expenses existed in the prior year periods;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | · | Increased research and clinical operations headcount and related costs;
| | - | -----------------------------------------------------------------------

| | · | Formulation and manufacturing costs associated with APTO-253 and the root cause analysis of the
filter clogging identified in November 2015; and
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------

| | · | Increased Contract Research Organization costs related to consultants and advisors as we work towards
returning APTO-253 to the clinic.
| | - | ---------------------------------------------------------------------------------------------------------------------------------------



During the year ended December 31, 2016, we paid US$1.0 million
(CA$1.294 million) to CG for an option fee related to the CG’806 technology. Should we elect to exercise the option prior
to filing of an IND application with the FDA, we would pay an additional US$2.0 million in cash or combination of cash and common
shares, and would receive full development and commercial rights for the program in all territories outside of Korea and China.
No comparable expense existed in the same period in the prior year.



Expenditures for the year ended December 31, 2015 increased significantly
over the seven months ended December 31, 2014 (on an annualized basis) due to the following:



| | · | Costs associated with the Phase 1b clinical trial of APTO-253 in
patients with relapsed or refractory hematologic malignancies including clinical site costs, patient costs, contract research
organization and consulting charges. The first patient in the trial was enrolled in January 2015;
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | · | Development costs related to the Moffitt/LALS programs which were initiated in the fourth quarter
of 2015;
| | - | ----------------------------------------------------------------------------------------------------------

| | · | Formulation, manufacturing and compliance costs related to the development of APTO-253 including
costs related to the clinical hold described above;
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------

| | · | Additional payroll related costs in the clinical department due to restructuring to support ongoing
activities; and
| | - | -------------------------------------------------------------------------------------------------------------------

| | · | The increased cost of US dollar denominated expenditures due to the devaluation of the CDN dollar
in 2015.
| | - | ----------------------------------------------------------------------------------------------------------



Stock-based compensation costs allocated to research and development
increased in the year ended December 31, 2016 compared with the year ended December 31, 2015 to reflect option grants to new employees
hired in the second half of 2015 as the expense related to those grants was amortized 50% in the first 12 months.



Stock-based compensation expense increased in the year ended December
31, 2015 compared with the seven months ended December 31, 2014 primarily due to option grants to new employees and advisors during
the year.





8




General
and Administrative

General and administrative expenses totaled $8.3 million in the
year ended December 31, 2016 compared to $9.8 million in the year ended December 31, 2015 and $5.5 million in the seven months
ended December 31, 2014.



Components of general and administrative expenses:

|                                              |  |              |       |  |              |   |       |                | 
|--------------------------------------------- |  | ------------ | ----- |  | ------------ | - | ----- | -------------- | 
|                                              |  | Year ended   |       |  | Year ended   |   |       | 7 months ended | 
|                                              |  | December 31, |       |  | December 31, |   |       | December 31,   | 
|                                              |  | 2016         |       |  | 2015         |   |       | 2014           | 
|                                              |  |              |       |  |              |   |       |                | 
|                                              |  |              |       |  |              |   |       |                | 
|General and administrative excluding salaries |  | $            | 3,412 |  |              | $ | 4,317 |                | 
|Salaries                                      |  |              | 3,095 |  |              |   | 2,859 |                | 
|Stock-based compensation                      |  |              | 1,730 |  |              |   | 2,602 |                | 
|Depreciation of equipment and amortisation    |  |              | 107   |  |              |   | 67    |                | 
|                                              |  | $            | 8,344 |  |              | $ | 9,845 |                | 



General and administrative expenses excluding salaries, decreased
in the year ended December 31, 2016 compared with the year ended December 31, 2015. The decrease is the result of lower travel,
consulting and legal costs in the current year related to transactions completed in the prior year as well as lower press release
and filing costs associated with a lower cost service provider in the current year periods.



Salary charges in the year ended December 31, 2016 increased in
comparison with the year ended December 31, 2015 due to additional headcount in the first half of 2016 compared with the first
half of 2015 as well as a higher average CA/US exchange rate which increased the cost of our US denominated salaries in the first
six months of 2016 in comparison with the prior year, and higher bonus expense recognized in the current period.



Stock-based compensation decreased in the year ended December 31,
2016 compared with the year ended December 31, 2015 due to large option grants in April, June and July 2014 which vested 50% during
the first year and therefore contribute to higher stock-based compensation expense during the first twelve month period captured
in the prior year period.



Stock-based compensation expense increased in the year ended December
31, 2015 compared with the seven months ended December 31, 2014 primarily due to option grants to new employees and advisors during
the year.



Finance Expense

For the year ended December 31, 2016, finance expense totaled $66
thousand compared with $43 thousand for the same period in the prior year. Finance expense includes the following items:

|                                                   |  |              |    |  |              |   |    |                | 
|-------------------------------------------------- |  | ------------ | -- |  | ------------ | - | -- | -------------- | 
|                                                   |  | Year ended   |    |  | Year ended   |   |    | 7 months ended | 
|                                                   |  | December 31, |    |  | December 31, |   |    | December 31,   | 
|                                                   |  | 2016         |    |  | 2015         |   |    | 2014           | 
|Interest expense                                   |  | $            | -  |  |              | $ | 25 |                | 
|Accretion expense                                  |  |              | -  |  |              |   | 18 |                | 
|Foreign exchange loss on cash and cash equivalents |  |              | 66 |  |              |   | -  |                | 
|                                                   |  | $            | 66 |  |              | $ | 43 |                | 



Interest and accretion expense incurred in the year ended December
31, 2015 and the seven months ended December 31, 2014 relates to the 10% convertible promissory notes described above. There were
no interest-bearing liabilities outstanding at December 31, 2015. Foreign exchange loss is the result of the fluctuation of exchange
rates between US and Canadian dollars and the impact on our US dollar denominated cash balances.





9




Finance Income

Finance income totaled $105 thousand in the year ended December
31, 2016 compared to $1.5 million in the year ended December 31, 2015.



Finance income includes the following items:

|                                  |  |              |     |  |              |   |       |                | 
|--------------------------------- |  | ------------ | --- |  | ------------ | - | ----- | -------------- | 
|                                  |  | Year ended   |     |  | Year ended   |   |       | 7 months ended | 
|                                  |  | December 31, |     |  | December 31, |   |       | December 31,   | 
|(in thousands)                    |  | 2016         |     |  | 2015         |   |       | 2014           | 
|                                  |  |              |     |  |              |   |       |                | 
|Interest income                   |  | $            | 105 |  |              | $ | 286   |                | 
|Foreign exchange gain on cash and |  |              |     |  |              |   |       |                | 
|cash equivalents                  |  |              | −   |  |              |   | 1,230 |                | 
|                                  |  | $            | 105 |  |              | $ | 1,516 |                | 



Interest income represents interest earned on our cash and cash
equivalent and investment balances. Foreign exchange gains are the result of an increase in the value of US dollar denominated
cash and cash equivalents balances during such periods due to a depreciation of the Canadian dollar compared to the US dollar.



Net loss and total comprehensive
loss for the year

For the reasons discussed above, our net loss for the year ended
December 31, 2016 increased to $18.6 million ($1.46 per share) compared to $14.6 million ($1.23 per share) in the year ended December
31, 2015.



QUARTERLY
FINANCIAL INFORMATION (UNAUDITED)



The selected financial information provided below is derived from
our unaudited quarterly financial statements for each of the last eight quarters.

|                                                    |  |              |        |   |               |   |        |               |  |   |              |   |  |              |        |   |               |   |        |               |  |   |              |  
|--------------------------------------------------- |  | ------------ | ------ | - | ------------- | - | ------ | ------------- |  | - | ------------ | - |  | ------------ | ------ | - | ------------- | - | ------ | ------------- |  | - | ------------ | -
|                                                    |  | Q4           |        |   | Q3            |   |        | Q2            |  |   | Q1           |   |  | Q4           |        |   | Q3            |   |        | Q2            |  |   | Q1           |  
|(Amounts in 000’s except for per common share data) |  | Dec 31, 2016 |        |   | Sept 30, 2016 |   |        | June 30, 2016 |  |   | Mar 31, 2016 |   |  | Dec 31, 2015 |        |   | Sept 30, 2015 |   |        | June 30, 2015 |  |   | Mar 31, 2015 |  
|Revenue                                             |  | $            | ―      |   |               | $ | ―      |               |  | $ | ―            |   |  | $            | ―      |   |               | $ | ―      |               |  | $ | ―            |  
|Research and development expense                    |  |              | 2,550  |   |               |   | 2,164  |               |  |   | 3,293        |   |  |              | 2,315  |   |               |   | 2,340  |               |  |   | 1,722        |  
|General and administrative expense                  |  |              | 1,461  |   |               |   | 1,932  |               |  |   | 2,343        |   |  |              | 2,608  |   |               |   | 2,364  |               |  |   | 2,248        |  
|Net loss                                            |  |              | (3,926 | ) |               |   | (4,017 | )             |  |   | (5,612       | ) |  |              | (5,072 | ) |               |   | (4,431 | )             |  |   | (3,261       | )
|Basic and diluted net loss per share                |  | $            | (0.26  | ) |               | $ | (0.31  | )             |  | $ | (0.46        | ) |  | $            | (0.42  | ) |               | $ | (0.38  | )             |  | $ | (0.27        | )
|Cash (used in) operating activities                 |  | $            | (3,984 | ) |               | $ | (3,277 | )             |  | $ | (4,648       | ) |  | $            | (4,523 | ) |               | $ | (3,619 | )             |  | $ | (2,567       | )



Research and development expenditures increased in the three months
ended June 30, 2016 due to the $1.294 million option fee paid to CG as previously described herein. Research and development expenses
increased in the quarters ended December 31, 2016, September 30, 2016, March 31, 2016 and December 31, 2015 in comparison to the
prior year quarters due to the Phase 1b clinical trial of APTO-253 for which the first patient was enrolled in January 2015 and
was subsequently placed on hold in November 2015, and the costs associated with the quality, manufacturing and formulation work
including the clinical hold previously described herein as well as costs related to the collaboration agreement with Moffitt and
LALS.



General and administrative costs increased in the three months ended
March 31, 2016 due to our US dollar expenses and payroll costs which were more costly due to the devaluation of the Canadian dollar
over that time period. The decrease in general and administrative costs in the three months ended September 30, 2016 and December
31, 2016 is primarily due to lower stock based compensation expense and the completion of certain projects.



Cash used in operating activities fluctuates significantly due primarily
to timing of payments and increases and decreases in the accounts payables and accrued liabilities balances.





10




Three
months ended december 31, 2016 and 2015 (unaudited)

|                                                    |  |              |       |   |              |  
|--------------------------------------------------- |  | ------------ | ----- | - | ------------ | -
|(Amounts in 000’s except for per common share data) |  | Dec 31, 2016 |       |   | Dec 31, 2015 |  
|Revenue                                             |  | $            | ―     |   |              | $
|Research and development expense                    |  |              | 2,550 |   |              |  
|General and administrative expense                  |  |              | 1,461 |   |              |  
|Operating expenses                                  |  |              | 4,011 |   |              |  
|Finance expense                                     |  |              | ―     |   |              |  
|Finance income                                      |  |              | (85   | ) |              |  
|Net financing income                                |  |              | (85   | ) |              |  
|Net loss                                            |  |              | 3,926 |   |              |  
|Basic and diluted  net loss per share               |  | $            | (0.26 | ) |              | $



Our net loss for the three months ended December 31, 2016 was $3.9
million ($0.26 per share) compared with $4.4 million ($0.38 per share) in the same period in the prior year.



Research and development costs increased to $2.6 million in the
three months ended December 31, 2016 compared with $2.3 million incurred in the three months ended December 2015. The Company incurred
higher costs for formulation studies and manufacturing costs for the APTO-253 product in the three months ended December 31, 2016
than in the comparable period, and these were offset by lower expenses for the contract research organization costs to manage the
study. In addition, in the current period the Company was conducting studies related to its CG’806 program following the
licensing of the technology in June 2016.



General and administrative expenses decreased to $1.5 million in
the three months ended December 31, 2016 compared with $2.4 million in the three months ended December 31, 2015. The decrease despite
the increased cost of our US dollar expenditures due to the devaluation of the Canadian dollar is related to lower stock option
compensation and lower consulting fees related to projects that were active and completed in the prior quarter.



use
of proceeds



The following table provides an update on the anticipated use of
proceeds raised in the December 2013 and April 2014 equity offerings along with amounts actually expended.



As of December 31, 2016 the following expenditures have been incurred:





|(in thousands)                                                                                                                                                     |  |   | Previously 
disclosed |  |  |   | Spent to
Date |  |  |   | Remaining 
to be spent 
(note 1) | 
|------------------------------------------------------------------------------------------------------------------------------------------------------------------ |  | - | --------------------- |  |  | - | ------------- |  |  | - | -------------------------------- | 
|Phase 1b clinical trial                                                                                                                                            |  | $ | 3,350                 |  |  | $ | 2,964         |  |  | $ | 260                              | 
|Depending on the Phase 1b clinical trial of APTO-253 results, fund single agent expansion and drug combination focused Phase 2 Trials in both AML and MDS patients |  | $ | 7,800                 |  |  | $ | nil           |  |  | $ | nil                              | 
|APTO-253 manufacturing program, including root cause and CAPA studies                                                                                              |  | $ | 2,250                 |  |  | $ | 2,811         |  |  | $ | 1,000                            | 
|Research and development programs                                                                                                                                  |  | $ | 2,000                 |  |  | $ | 3,155         |  |  | $ | 1,771                            | 
|General and corporate purposes                                                                                                                                     |  | $ | 15,869                |  |  | $ | 17,008        |  |  | $ | 2,300                            | 
|                                                                                                                                                                   |  | $ | 31,269                |  |  | $ | 25,938        |  |  | $ | 5,331                            | 





Note 1: these amounts reflect the expected allocation of the remaining
$5.3 million in proceeds from the December 2013 and April 2014 equity offerings. In accordance with our recent decision to prioritize
our resources toward the development of CG’806 and to temporarily delay clinical activities with APTO-253, we have decided
to reallocate such remaining amount to the following CG’806 development plans: to determine root cause analysis of manufacturing
concerns for APTO-253 and for general corporate purposes.





11




The Company has other cash available to fund future operations as
a result of other capital raises for which no allocation was stipulated.



CRITICAL
ACCOUNTING POLICIES



Critical
Accounting Policies and Estimates

We periodically review our financial reporting and disclosure practices
and accounting policies to ensure that they provide accurate and transparent information relative to the current economic and business
environment. As part of this process, Aptose has reviewed its selection, application and communication of critical accounting policies
and financial disclosures. Management has discussed the development and selection of the critical accounting policies with the
Audit Committee of the Board of Directors and the Audit Committee has reviewed the disclosure relating to critical accounting policies
in this MD&A. Other important accounting policies are described in note 3 of the audited financial statements.



Management’s assessment of the Company’s ability to
continue as a going concern involves making a judgment, at a particular point in time, about inherently uncertain future outcomes
and events or conditions. Please see the “Liquidity and Capital Resources” section in this document for a discussion
of the factors considered by management in arriving at its assessment.



(a) Valuation of stock-based compensation and share purchase
warrants:

Management measures the costs for stock-based payments and share
purchase warrants using market-based option valuation techniques. Assumptions are made and judgment is used in applying valuation
techniques. These assumptions and judgments include estimating the future volatility of the share price, expected dividend yield,
future employee turnover rates and future share option and share purchase warrant behaviors and corporate performance. Such judgments
and assumptions are inherently uncertain. The increase or decrease of one of these assumptions could materially increase or decrease
the fair value of share-based compensation and share purchase warrants issued and the associated expense.



(b) Valuation of tax accounts:

Uncertainties exist with respect to the interpretation of complex
tax regulations and the amount and timing of future taxable income. Currently, we have deductible temporary differences which would
create a deferred tax asset. Deferred tax assets are recognized for all deductible temporary differences to the extent that it
is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. Management
judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the
level of future taxable profits together with future tax planning strategies. To date, we have determined that none of our deferred
tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years and
prior year research and development expenses. These tax pools relate to entities that have a history of losses, have varying expiry
dates, and may not be used to offset taxable income. As well, there are no taxable temporary differences or any tax planning opportunities
available that could partly support the recognition of these losses as deferred tax assets. The generation of future taxable income
could result in the recognition of some portion or all of the remaining benefits, which could result in an improvement in our results
of operations through the recovery of future income taxes.



(c) Valuation of contingent liabilities:

We utilize considerable judgment in the measurement and recognition
of provisions and Aptose’s exposure to contingent liabilities. Judgment is required to assess and determine the likelihood
that any potential or pending litigation or any and all potential claims against us may be successful. We must estimate if an
obligation is probable as well as quantify the possible economic cost of any claim or contingent liability. Such judgments and
assumptions are inherently uncertain. The increase or decrease of one of these assumptions could materially increase or decrease
the fair value of the liability and the associated expense.



Accounting
pronouncements adopted during the year



Amendments to IAS 1

Effective January 1, 2016, the Company adopted the amendments to
IAS1 Presentation of Financial Statements issued by the IASB in December 2014. The impact of adoption of these amendments
did not to have a material impact on the financial statements.



Recent
Accounting pronouncements not yet adopted



IFRS 9, Financial Instruments ("IFRS 9"):

IFRS 9 (2014) introduces new requirements for the classification
and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based on the business model
in which they are held and the characteristics of their contractual cash flows. The standard introduces additional changes relating
to financial liabilities and also amends the impairment model by introducing a new ‘expected credit loss’ model for
calculating impairment. IFRS 9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting
more closely with risk management. The Company intends to adopt IFRS 9 (2014) in its consolidated financial statements for the
annual period beginning on January 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.





12




IFRS 16, Leases (“IFRS 16”)

On January 13, 2016, the IASB issued IFRS 16 Leases. The new standard
is effective for annual periods beginning on or after January 1, 2019. Earlier application is permitted for entities that apply
IFRS 15 Revenue from Contracts with Customers at or before the date of initial adoption of IFRS 16. IFRS 16 will replace IAS 17
Leases. This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for
all leases with a term of more than 12 months, unless the underlying asset is of low value. The extent of the impact of adoption
of the standard has not yet been determined.



Recognition of Deferred Tax Assets for Unrealized Losses (Amendments
to IAS 12)

On January 19, 2016 the IASB issued Recognition of Deferred Tax
Assets for Unrealized Losse (Amendments to IAS 12). The amendments apply retrospectively for annual periods beginning on or after
January 1, 2017. Earlier application is permitted. The extent of the impact of adoption of the standard has not yet been determined.



Related
Party Transactions



In March 2015, the Company entered into an agreement with the Moores
Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen
Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and will be overseeing the laboratory
work. The research services will be provided from April 1, 2015 to March 31, 2016 for an annual fee of US$154,456 to be paid to
UCSD in monthly installments. This research services agreement was approved by the Aptose Board of Directors on February 23, 2016
for an additional 12 month period beginning April 1, 2016 and for an annual fee of up to US$200,000. This transaction is in the
normal course of business and will be measured at the amount of consideration established and agreed to by the related parties.



See note 14 to the audited financial statements for disclosures
of key management personnel compensation and directors’ compensation.



Contractual Obligations and Off-Balance
Sheet Financing



AtDecember 31, 2016, we
had contractual obligations requiring annual payments as follows:

|                 |  |                  |     |  |             |   |     |             |  |   |       | 
|---------------- |  | ---------------- | --- |  | ----------- | - | --- | ----------- |  | - | ----- | 
|                 |  | Less than 1 year |     |  | 1 - 3 years |   |     | 3 - 5 years |  |   | Total | 
|Operating leases |  | $                | 358 |  |             | $ | 649 |             |  | $ | 59    | 



The Company has entered into various contracts with service providers
with respect to the clinical development of APTO-253 and for its CG’806 development program. These contracts will result
in future payments commitments of up to $430 thousand.



As at December 31, 2016, we have not entered into any off-balance
sheet arrangements other than the operating leases for our offices and labs and certain office equipment.



Financial
instruments



(a) Financial instruments

|                                          |  |      |        |  |      |  
|----------------------------------------- |  | ---- | ------ |  | ---- | -
|(in thousands)                            |  | 2015 |        |  | 2014 |  
|                                          |  |      |        |  |      |  
|Financial assets:                         |  |      |        |  |      |  
|Cash and cash equivalents, consisting     |  |      |        |  |      |  
|of high interest savings accounts,        |  |      |        |  |      |  
|measured at amortized cost                |  | $    | 10,662 |  |      | $
|Investments, consisting of                |  |      |        |  |      |  
|guaranteed investment certificates,       |  |      |        |  |      |  
|measured at amortized cost.               |  |      | -      |  |      |  
|                                          |  |      |        |  |      |  
|Financial liabilities:                    |  |      |        |  |      |  
|Accounts payable and accrued liabilities, |  |      |        |  |      |  
|measured at amortized cost                |  |      | 1,770  |  |      |  





13




At December 31, 2016, there are no significant differences between the carrying values
of these amounts and their estimated market values due to their short-term nature.



(b) Financial risk management



We have exposure to credit risk, liquidity risk and market
risk. Our Board of Directors has the overall responsibility for the oversight of these risks and reviews our policies on an ongoing
basis to ensure that these risks are appropriately managed.



(i) Credit risk



Credit risk is the risk of financial loss to us if a customer,
partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from our cash
and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure.



We manage credit risk for our cash and cash equivalents
and investments by maintaining minimum standards of R1-low or A-low investments and we invest only in highly rated Canadian corporations
with debt securities that are traded on active markets and are capable of prompt liquidation.



(ii) Liquidity risk



Liquidity risk is the risk that we will not be able to
meet our financial obligations as they come due. To the extent that we do not believe we have sufficient liquidity to meet our
current obligations, the Board considers securing additional funds through equity or debt transactions. We manage our liquidity
risk by continuously monitoring forecasts and actual cash flows. All of our financial liabilities are due within the current operating
period.



(iii) Market risk



Market risk is the risk that changes in market prices,
such as interest rates, foreign exchange rates and equity prices will affect our income or the value of our financial instruments.



We are subject to interest rate risk on our cash and cash
equivalents however we do not believe that the results of operations or cash flows would be affected to any significant degree
by a sudden change in market interest rates relative to interest rates on the investments, owing to the relative short-term nature
of the investments. We do not have any material interest bearing liabilities subject to interest rate fluctuations.



Currency risk is the risk that future cash flows of a
financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from employee
costs as well as the purchase of goods and services primarily in the United States and the cash balances held in foreign currencies.
Fluctuations in the US dollar exchange rate could potentially have a significant impact on the Company’s results. Assuming
all other variables remain constant, a 10% depreciation or appreciation of the Canadian dollar against the US dollar would result
in an increase or decrease in loss for the year and comprehensive loss of $638 thousand (December 31, 2015- $576 thousand, December
31, 2014 - $50 thousand). Balances in foreign currencies at December 30, 2016 are as follows:

|                                         |  |              |       
|---------------------------------------- |  | ------------ | ------
|                                         |  | US$ Balances |       
|                                         |  | December 31, |       
|(in thousands)                           |  | 2016         |       
|                                         |  |              |       
|Cash and cash equivalents                |  | $            | 5,798 
|Accounts payable and accrued liabilities |  |              | (1,044
|Balance, end of period                   |  | $            | 4,754 



The Company does not have any forward exchange contracts
to hedge this risk.



The Company does not invest in equity instruments of other
corporations.



(c) Capital management



Our primary objective when managing capital is to ensure
that we have sufficient cash resources to fund our development activities and to maintain our ongoing operations. To secure the
additional capital necessary to pursue these plans, we may attempt to raise additional funds through the issuance of equity or
by securing strategic partners.



We include cash and cash equivalents and investments in
the definition of capital.



We are not subject to externally imposed capital requirements
and there has been no change with respect to the overall capital risk management strategy during the year ended December 31, 2016.



14






Outlook



Until
one of our drug candidates receives regulatory approval and is successfully commercialized, Aptose will continue to incur operating
losses. The magnitude of these operating losses will be largely affected by the timing and scope of future research and development,
clinical trials and the Company’s ability to raise additional and ongoing working capital and/or establish effective partnerships
to share the costs of development and clinical trials.



RISK
FACTORS



Investing in our securities involves a high degree of risk. Before
making an investment decision with respect to our common shares, you should carefully consider the following risk factors, in addition
to the other information included or incorporated by reference into the most recently filed annual information form, as well as
our historical consolidated financial statements and related notes. Management has reviewed the operations of the Company in conjunction
with the Board of Directors and identified the following risk factors which are monitored on a bi-annual basis and reviewed with
the Board of Directors. The risks set out below are not the only risks we face. If any of the following risks occur, our business,
financial condition, prospects or results of operations and cash flows would likely suffer. In that case, the trading price of
our common shares could decline and you may lose all or part of the money you paid to buy our common shares



We have a history of operating losses. We expect to incur
net losses and we may never achieve or maintain profitability.



We have not been profitable since our inception
in 1986. We reported net losses of $18.6 million in the fiscal year ended December 31, 2016, $14.6 million in the fiscal year ended
December 31, 2015, and $7.8 million in the 7 months ended December 31, 2014, and as of December 31, 2016, we had an accumulated
deficit of $251.5 million.



We have not generated any significant revenue
to date and it is possible that we will never have sufficient product sales revenue (if any) to achieve profitability. We expect
to continue to incur losses for at least the next several years as we or our collaborators and licensees pursue clinical trials
and research and development efforts. To become profitable, we, either alone or with our collaborators and licensees, must successfully
develop, manufacture and market our current product candidates CG’806 or APTO-253 as well as continue to identify, develop,
manufacture and market new product candidates. It is possible that we will never have significant product sales revenue or receive
royalties on our licensed product candidates. If funding is insufficient at any time in the future, we may not be able to develop
or commercialize our products, take advantage of business opportunities or respond to competitive pressures.



We are an early stage development company.



We are at an early stage of development. In
the past five years, none of our potential products has obtained regulatory approval for commercial use and sale in any country
and as such, no significant revenues have resulted from product sales. Significant additional investment will be necessary to complete
the development of any of our product candidates. Preclinical and clinical trial work must be completed before our potential products
could be ready for use within the markets that we have identified. We may fail to develop any products, obtain regulatory approvals,
enter clinical trials or commercialize any products. We do not know whether any of our potential product development efforts will
prove to be effective, meet applicable regulatory standards, obtain the requisite regulatory approvals, be capable of being manufactured
at a reasonable cost or be accepted in the marketplace. We also do not know whether sales, license fees or related royalties will
allow us to recoup any investment we make in the commercialization of our products.



The product candidates we are currently developing
are not expected to be commercially viable for at least the next several years and we may encounter unforeseen difficulties or
delays in commercializing our product candidates. In addition, our potential products may not be effective or may cause undesirable
side effects.



Our product candidates require significant
funding to reach regulatory approval assuming positive clinical results. For example, our product candidate APTO-253 began enrolment
in a Phase I clinical trial in patients with relapsed or refractory hematologic malignancies and was placed on clinical hold by
the United States Food and Drug Administration (“FDA”) following a voluntary suspension of dosing by us. We
are currently delaying the development of APTO-253 but significant additional funding or a partnership will be necessary to complete,
if required, Phase II or Phase III clinical trials. Such funding may be very difficult, or impossible to raise in the public or
private markets or through partnerships. If funding or partnerships are not attainable, the development of these product candidates
may be significantly delayed or stopped altogether. The announcement of a delay or discontinuation of development would likely
have a negative impact on our share price.





15




We need to raise additional capital.



We have an ongoing need to raise additional
capital. To obtain the necessary capital, we must rely on some or all of the following: additional share issues, debt issuances
(including promissory notes), collaboration agreements or corporate partnerships and grants and tax credits to provide full or
partial funding for our activities. Additional funding may not be available on terms that are acceptable to us or in amounts that
will enable us to carry out our business plan.



Our need for capital may require us to:



| | · | engage in equity financings that could result in significant dilution to existing investors;
| | - | --------------------------------------------------------------------------------------------

| | · | delay or reduce the scope of or eliminate one or more of our development programs;
| | - | ----------------------------------------------------------------------------------

| | · | obtain funds through arrangements with collaborators or others that may require us to relinquish
rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves; or
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | · | license rights to technologies, product candidates or products on terms that are less favourable
to us than might otherwise be available;
| | - | -----------------------------------------------------------------------------------------------------------------------------------------

| | · | considerably reduce operations; or
| | - | ----------------------------------

| | · | cease our operations.
| | - | ---------------------



Delays in clinical testing could result in delays in commercializing
our product candidates, and our business may be substantially harmed.



We cannot predict whether
any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product
development costs will increase if we experience delays in clinical testing. Significant clinical trial delays could shorten any
periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring
products to market before us, which would impair our ability to successfully commercialize our product candidates and may harm
our financial condition, results of operations and prospects. The commencement and completion of clinical trials for our products,
including the APTO-253 phase I clinical trial, may be delayed for a number of reasons, including delays related, but not limited,
to:



| | • |  | failure by regulatory authorities to grant permission to proceed or placing the clinical trial on hold;
| | - |  | -------------------------------------------------------------------------------------------------------



| | • |  | patients failing to enroll or remain in our trials at the rate we expect;
| | - |  | -------------------------------------------------------------------------



| | • |  | suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with cGMP requirements;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • |  | any changes to our manufacturing process that may be necessary or desired;
| | - |  | --------------------------------------------------------------------------



| | • |  | delays or failure to obtain clinical supply from contract manufacturers of our products necessary to conduct clinical trials;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------



| | • |  | product candidates demonstrating a lack of safety or efficacy during clinical trials;
| | - |  | -------------------------------------------------------------------------------------



| | • |  | patients choosing an alternative treatment for the indications for which we are developing any of our product candidates or participating in competing clinical trials;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • |  | patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;
| | - |  | ----------------------------------------------------------------------------------------------------------------------
| | • |  | reports of clinical testing on similar technologies and products raising safety and/or efficacy concerns;             



| | • |  | competing clinical trials and scheduling conflicts with participating clinicians;
| | - |  | ---------------------------------------------------------------------------------



| | • |  | clinical investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • |  | failure of our contract research organizations, or CROs, to satisfy their contractual duties or meet expected deadlines;
| | - |  | ------------------------------------------------------------------------------------------------------------------------



| | • |  | inspections of clinical trial sites by regulatory authorities or Institutional Review Boards, or IRBs, or ethics committees finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • |  | one or more IRBs or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • |  | failure to reach agreement on acceptable terms with prospective clinical trial sites.
| | - |  | -------------------------------------------------------------------------------------



Our product development
costs will increase if we experience delays in testing or approval or if we need to perform more or larger clinical trials than
planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend study protocols to reflect
these changes. Amendments may require us to resubmit our study protocols to regulatory authorities or IRBs or ethics committees
for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development
costs may have a material adverse effect on our business, financial condition and prospects.





16




We rely on contract manufacturers over whom we have limited
control. If we are subject to quality, cost or delivery issues with the preclinical and clinical grade materials supplied by contract
manufacturers, our business operations could suffer significant harm.



We rely on contract
manufacturing organizations, or CMOs, to manufacture our product candidates for some preclinical studies and clinical trials. We
rely on CMOs for manufacturing, filling, packaging, storing and shipping of drug product in compliance with cGMP regulations applicable
to our products. The FDA ensures the quality of drug products by carefully monitoring drug manufacturers’ compliance with
cGMP regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used in
manufacturing, processing and packing of a drug product.

We have contracted
with multiple CMOs for the manufacture of APTO-253 to supply both the API as well as to perform formulation and optimization studies
with the intent of supplying drug product acceptable to the FDA for our phase I clinical trial. The formulation and manufacture
of APTO-253 is a complex process with many variables involved. We believe these pre-qualified CMOs have the capacity, the systems
and the experience to supply APTO-253 for our phase I clinical trial and future clinical trials. We have qualified the manufacturing
facilities and the FDA has also performed site audits for our selected CMOs. Any manufacturing failures, delays or compliance issues
could cause further delays in the re-initiation of the phase I clinical trial. If we are able to re-initiate the phase I clinical
trial any manufacturing failures, delays or compliance issues could impact our ability to complete the phase I clinical trial.



There can be no assurances
that CMOs will be able to meet our timetable and requirements. We have not contracted with alternate suppliers in the event our
current CMOs are unable to scale up production, or if our current CMOs otherwise experience any other significant problems. If
we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner,
we may be further delayed in the development of our product candidates. Further, contract manufacturers must operate in compliance
with cGMP and failure to do so could result in, among other things, the disruption of product supplies. Our dependence upon third
parties for the manufacture of our products may adversely affect our profit margins and our ability to develop and deliver products
on a timely and competitive basis.



Clinical trials are long, expensive and uncertain processes
and the United States FDA or Health Canada may ultimately not approve any of our product candidates. We may never develop any commercial
drugs or other products that generate revenues.



In the past five years, none of our product
candidates has received regulatory approval for commercial use and sale in North America. We cannot market a pharmaceutical product
in any jurisdiction until it has completed thorough preclinical testing and clinical trials in addition to that jurisdiction’s
extensive regulatory approval process. Approval in one country does not assure approval in another country. In general, significant
research and development and clinical studies are required to demonstrate the safety and effectiveness of our product candidates
before we can submit any regulatory applications.



Clinical trials are long, expensive and uncertain
processes. Clinical trials may not be commenced or completed on schedule and the FDA or Health Canada or any other regulatory body
may not ultimately approve our product candidates for commercial sale. The clinical trials of any of our drug candidates could
be unsuccessful, which would prevent us from advancing, commercializing or partnering the drug.



Even if the results of our preclinical studies
or clinical trials are initially positive, it is possible that we will obtain different results in the later stages of drug development
or that results seen in clinical trials will not continue with longer term treatment. Positive results in Phase I clinical trials
may not be repeated in larger Phase II or Phase III clinical trials.



Our preclinical studies and clinical trials
may not generate positive results that will allow us to move towards the commercial use and sale of our product candidates. Furthermore,
negative preclinical or clinical trial results may cause our business, financial condition, or results of operations to be materially
adversely affected. For example, our product candidate APTO-253 has entered a Phase Ib testing in patients with relapsed or refractory
hematologic malignancies for which there is a long development path ahead that will take many years to complete and is prone to
the risks of failure or delays inherent in drug development and we delayed its development due to a lack of resources.



Preparing, submitting and advancing applications
for regulatory approval is complex, expensive and time intensive and entails significant uncertainty. A commitment of substantial
resources to conduct time-consuming research, preclinical studies and clinical trials is required if we are to complete development
of our products.



Clinical trials of our products require that
we identify and enroll a large number of patients with the illness under investigation. We may not be able to enroll a sufficient
number of appropriate patients to complete our clinical trials in a timely manner, particularly in smaller indications and indications
where there is significant competition for patients. If we experience difficulty in enrolling a sufficient number of patients to
conduct our clinical trials, we may need to delay or terminate ongoing clinical trials and will not accomplish objectives material
to our success. Delays in planned patient enrolment or lower than anticipated event rates in our current clinical trials or future
clinical trials also may result in increased costs, program delays, or both.





17




In addition, unacceptable toxicities or adverse
side effects may occur at any time in the course of preclinical studies or human clinical trials or, if any product candidates
are successfully developed and approved for marketing, during commercial use of any approved products. The appearance of any unacceptable
toxicities or adverse side effects could interrupt, limit, delay or abort the development of any of our product candidates or,
if previously approved, necessitate their withdrawal from the market. Furthermore, disease resistance or other unforeseen factors
may limit the effectiveness of our potential products.



Our failure to develop safe, commercially viable
drugs would substantially impair our ability to generate revenues and sustain our operations and would materially harm our business
and adversely affect our share price.



We may not achieve our projected development goals in the time frames we announce
and expect.



We set goals for, and make public statements
regarding, the expected timing of the accomplishment of objectives material to our success, such as the commencement and completion
of clinical trials and our ability to secure the financing necessary to continue the development of our product candidates. The
actual timing of these events can vary dramatically due to factors within and beyond our control, such as delays or failures in
our clinical trials, issues related to the manufacturing of drug supply, uncertainties inherent in the regulatory approval process,
market conditions and interest by partners in our product candidates among other things. Our clinical trials may not be completed;
we may not make regulatory submissions or receive regulatory approvals as planned; or we may not secure partnerships for any of
our product candidates. Any failure to achieve one or more of these milestones as planned would have a material adverse effect
on our business, financial condition and results of operations.



If we have difficulty enrolling patients in clinical trials,
the completion of the trials may be delayed or cancelled.



As our product candidates
advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, we
will need to enroll an increasing number of patients that meet our eligibility criteria. There is significant competition for recruiting
cancer patients in clinical trials, and we may be unable to enroll the patients we need to complete clinical trials on a timely
basis or at all. Certain factors that affect enrollment of patients onto our clinical trials are impacted by external forces that
may be beyond our control. Such factors include, but are not limited to, the following:



| | • |  | size and nature of the patient population;
| | - |  | ------------------------------------------



| | • |  | eligibility and exclusion criteria for the trial;
| | - |  | -------------------------------------------------



| | • |  | design of the study protocol;
| | - |  | -----------------------------



| | • |  | competition with other companies for clinical sites or patients;
| | - |  | ----------------------------------------------------------------



| | • |  | the perceived risks and benefits of the product candidate under study;
| | - |  | ----------------------------------------------------------------------



| | • |  | the patient referral practices of physicians; and
| | - |  | -------------------------------------------------



| | • |  | the number, availability, location and accessibility of clinical trial sites.
| | - |  | -----------------------------------------------------------------------------



If we are unable to successfully
develop companion diagnostics for our therapeutic product candidates, or experience significant delays in doing so, we may not
achieve marketing approval or realize the full commercial potential of our therapeutic product candidates.



We plan to develop
companion diagnostics for our therapeutic product candidates. We expect that, at least in some cases, regulatory authorities may
require the development and regulatory approval of a companion diagnostic as a condition to approving our therapeutic product candidates.
We have limited experience and capabilities in developing or commercializing diagnostics and plan to rely in large part on third
parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize
companion diagnostics for any of our therapeutic product candidates.



Companion diagnostics
are subject to regulation by the FDA, Health Canada and comparable foreign regulatory authorities as medical devices and may require
separate regulatory approval or clearance prior to commercialization. If we, or any third parties that we engage to assist
us, are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience delays in doing
so, our business may be substantially harmed.



We rely and will continue to rely
on third parties to conduct and monitor many of our preclinical studies and our clinical trials, and their failure to perform as
required could cause substantial harm to our business.



We rely and will continue
to rely on third parties to conduct a significant portion of our preclinical and clinical development activities. Preclinical activities
include in vivo studies providing access to specific disease models, pharmacology and toxicology studies, and assay development.
Clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring,
clinical data management and analysis, safety monitoring and project management, contract manufacturing and quality assurance.
If there is any dispute or disruption in our relationship with third parties, or if they are unable to provide quality services
in a timely manner and at a feasible cost, our active development programs will face delays. Further, if any of these third parties
fails to perform as we expect or if their work fails to meet regulatory requirements, our testing could be delayed, cancelled or
rendered ineffective.





18




We heavily rely on the capabilities
and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our products.



The loss of Dr. William
G. Rice, our Chairman, President and Chief Executive Officer, or other key members of our staff, including Gregory Chow, our Senior
Vice President and Chief Financial Officer, could harm us. We have employment agreements with Dr. Rice and Mr. Chow although such
employment agreements do not guarantee their retention. We also depend on our scientific and clinical collaborators and advisors,
all of whom have outside commitments that may limit their availability to us. In addition, we believe that our future success will
depend in large part upon our ability to attract and retain highly skilled scientific, managerial, medical, clinical and regulatory
personnel, particularly as we expand our activities and seek regulatory approvals for clinical trials. We routinely enter into
consulting agreements with our scientific and clinical collaborators and advisors, key opinion leaders and academic partners in
the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who will recruit
patients into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we
face significant competition for these types of personnel from other companies, research and academic institutions, government
entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth.
The loss of the services of any of our executive officers or other key personnel could potentially harm our business, operating
results or financial condition.



Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our
business.



We are exposed to the
risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, provide
accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care
fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us.
In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials,
which could result in regulatory sanctions and serious harm to our reputation. If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a substantial impact on our business
and results of operations, including the imposition of substantial fines or other sanctions.



We may expand our business through the acquisition of
companies or businesses or by entering into collaborations or by in-licensing product candidates, each of which could disrupt our
business and harm our financial condition.



We may in the future seek to expand our
pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations or in-licensing one or
more product candidates. For example in November 2015 we licensed intellectual property from the Moffittt Cancer Center for
exclusive global rights to potent, multi-targeting, single-agent inhibitors for the treatment of hematologic and solid tumor cancers.



Acquisitions, collaborations and in-licenses
involve numerous risks, including, but not limited to:



| | • |  | substantial cash expenditures;
| | - |  | ------------------------------



| | • |  | technology development risks;
| | - |  | -----------------------------



| | • |  | potentially dilutive issuances of equity securities;
| | - |  | ----------------------------------------------------



| | • |  | incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------



| | • |  | difficulties in assimilating the operations of the acquired companies;
| | - |  | ----------------------------------------------------------------------



| | • |  | potential disputes regarding contingent consideration;
| | - |  | ------------------------------------------------------



| | • |  | diverting our management’s attention away from other business concerns;
| | - |  | -----------------------------------------------------------------------



| | • |  | entering markets in which we have limited or no direct experience;
| | - |  | ------------------------------------------------------------------



| | • |  | potential loss of our key employees or key employees of the acquired companies
or businesses; and
| | - |  | -------------------------------------------------------------------------------------------------



| | • |  | failure of the in-licensed agents or technologies to deliver the desired activities or
        functions.
| | - |  | ---------------------------------------------------------------------------------------------------------



We have experience
in entering collaborations and in-licensing product candidates, however, we cannot provide assurance that any acquisition, collaboration
or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
company or business or in-licensed product candidate. In addition, our future success would depend in part on our ability to manage
the rapid growth associated with some of these acquisitions, collaborations and in-licenses. We cannot assure you that we would
be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate in-licensed
product candidates. Furthermore, the development or expansion of our business may require a substantial capital investment by us.





19




Negative results from clinical trials or studies of others
and adverse safety events involving the targets of our products may have an adverse impact on our future commercialization efforts.



From time to time,
studies or clinical trials on various aspects of biopharmaceutical products are conducted by academic researchers, competitors
or others. The results of these studies or trials, when published, may have a significant effect on the market for the biopharmaceutical
product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events
related to our product candidates, or the therapeutic areas in which our product candidates compete, could adversely affect our
share price and our ability to finance future development of our product candidates, and our business and financial results could
be materially and adversely affected.



As a result of intense competition and technological change
in the biotechnical and pharmaceutical industries, the marketplace may not accept our products or product candidates, and we may
not be able to compete successfully against other companies in our industry and achieve profitability.



Many of our competitors have:



| | · | drug products that have already been approved or are in development, and operate large, well-funded
research and development programs in the biotechnical and pharmaceutical fields;
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | · | substantially greater financial, technical and management resources, stronger intellectual property
positions and greater manufacturing, marketing and sales capabilities, areas in which we have limited or no experience; and
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | · | significantly greater experience than we do in undertaking preclinical testing and clinical trials
of new or improved pharmaceutical products and obtaining required regulatory approvals.
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Consequently, our competitors may obtain FDA,
Health Canada and other regulatory approvals for product candidates sooner and may be more successful in manufacturing and marketing
their products than we or our collaborators are.



Our competitor’s existing and future products,
therapies and technological approaches will compete directly with the products we seek to develop. Current and prospective competing
products may be more effective than our existing and future products insofar as they may provide greater therapeutic benefits for
a specific problem or may offer easier delivery or comparable performance at a lower cost.



Any product candidate that we develop and that
obtains regulatory approval must then compete for market acceptance and market share. Our products may not gain market acceptance
among physicians, patients, healthcare payers, insurers, the medical community and other stakeholders. Further, any products we
develop may become obsolete before we recover any expenses we incurred in connection with the development of these products. As
a result, we may never achieve profitability.



We may be unable to obtain patents to protect our technologies
from other companies with competitive products, and patents of other companies could prevent us from manufacturing, developing
or marketing our products.



Patent protection



The patent positions of pharmaceutical and biotechnology
companies are uncertain and involve complex legal and factual questions. The United States Patent and Trademark Office and many
other patent offices in the world have not established a consistent policy regarding the breadth of claims that they will allow
in biotechnology patents.



Our pending patent applications may not result
in issued patents and our issued patents may not be held valid and enforceable if challenged. Competitors may be able to circumvent
any such issued patents by adoption of a competitive, though non-infringing product or process. Interpretation and evaluation of
pharmaceutical or biotechnology patent claims present complex and often novel legal and factual questions. Our business could be
adversely affected by increased competition in the event that any patent granted to it is held to be invalid or unenforceable or
is inadequate in scope to protect our operations.



Allowable patentable subject matter and the
scope of patent protection obtainable may differ between jurisdictions. If a patent office allows broad claims, the number and
cost of patent interference proceedings in the United States, or analogous proceedings in other jurisdictions and the risk of infringement
litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the value of our rights under our
patents, licenses and patent applications may also decrease.



The scope of the claims in a patent application
can be significantly modified during prosecution before the patent is issued. Consequently, we cannot know whether our pending
applications will result in the issuance of patents or, if any patents are issued, whether they will provide us with significant
proprietary protection or will be circumvented, invalidated or found to be unenforceable.





20




Publication of discoveries in scientific or
patent literature often lags behind actual discoveries. Patent applications filed in the United States generally will be published
18 months after the filing date unless the applicant certifies that the invention will not be the subject of a foreign patent application.
In many other jurisdictions, such as Canada, patent applications are published 18 months from the priority date. We may not be
aware of such literature. Accordingly, we cannot be certain that the named inventors of our products and processes were the first
to invent that product or process or that we were the first to pursue patent coverage for our inventions.



In addition, U.S. patent laws may change which
could prevent or limit us from filing patent applications or patent claims in the United States to protect our products and technologies
or limit the exclusivity periods that are available to patent holders for U.S. patents. For example, the Leahy-Smith America Invents
Act, (the “Leahy-Smith Act”) was signed into law in 2011 and includes a number of significant changes to U.S.
patent law. These include changes to transition from a “first-to-invent” system to a “first-to-file” system
and to the way issued patents are challenged. These changes may favour larger and more established companies that have more resources
to devote to patent application filing and prosecution. It is not clear what, if any, impact the Leahy-Smith Act will ultimately
have on the cost of prosecuting our patent applications in the United States, our ability to obtain patents in the United States
based on our discoveries and our ability to enforce or defend our U.S. issued patents.



Until such time, if ever, that further patents
are issued to us, we will rely upon the law of trade secrets to the extent possible given the publication requirements under international
patent treaty laws and/or requirements under foreign patent laws to protect our technology and our products incorporating the technology.
In this regard, we have adopted certain confidentiality procedures. These include: limiting access to confidential information
to certain key personnel; requiring all directors, officers, employees and consultants and others who may have access to our intellectual
property to enter into confidentiality agreements which prohibit the use of or disclosure of confidential information to third
parties; and implementing physical security measures designed to restrict access to such confidential information and products.
Our ability to maintain the confidentiality of our technology is crucial to our ultimate possible commercial success. The procedures
adopted by us to protect the confidentiality of our technology may not be effective, third parties may gain access to our trade
secrets or disclose our confidential technology. Further, by seeking patent protection in various countries, it is inevitable that
a substantial portion of our technology will become available to our competitors, through publication of such patent applications.



Enforcement of intellectual property rights



Protection of the rights revealed in published
patent applications can be complex, costly and uncertain. Our commercial success depends in part on our ability to maintain and
enforce our proprietary rights. If third parties engage in activities that infringe our proprietary rights, our management’s
focus will be diverted and we may incur significant costs in asserting our rights. We may not be successful in asserting our proprietary
rights, which could result in our patents being held invalid or a court holding that the third party is not infringing, either
of which would harm our competitive position.



Others may design around our patented technology.
We may have to participate in interference proceedings declared by the United States Patent and Trademark Office, European opposition
proceedings, or other analogous proceedings in other parts of the world to determine priority of invention and the validity of
patent rights granted or applied for, which could result in substantial cost and delay, even if the eventual outcome is favourable
to us. Our pending patent applications, even if issued, may not be held valid or enforceable.



Trade secrets



We also rely on trade secrets, know-how and
confidentiality provisions in our agreements with our collaborators, employees and consultants to protect our intellectual property.
However, these and other parties may not comply with the terms of their agreements with us, and we might be unable to adequately
enforce our rights or obtain adequate compensation for the damages caused by unauthorized disclosure or use of our trade secrets
or know how. Our trade secrets or those of our collaborators also may be independently discovered by others.



Our products and product candidates may infringe the intellectual
property rights of others, or others may infringe on our intellectual property rights which could increase our costs.



Our success also depends on avoiding infringement
of the proprietary technologies of others. In particular, there may be certain issued patents and patent applications claiming
subject matter which we or our collaborators may be required to license in order to research, develop or commercialize APTO-253,
our lead product candidate. In addition, third parties may assert infringement or other intellectual property claims against us.
An adverse outcome in these proceedings could subject us to significant liabilities to third-parties, require disputed rights to
be licensed from third-parties or require us to cease or modify our use of the technology. If we are required to license third-party
technology, a license under such patents and patent applications may not be available on acceptable terms or at all. Further, we
may incur substantial costs defending ourselves in lawsuits against charges of patent infringement or other unlawful use of another’s
proprietary technology. We may also need to bring claims against others who we believe are infringing our rights in order to become
or remain competitive and successful. Any such claims can be time consuming and expensive to pursue.





21




We may incur substantial cost in defending our intellectual
property.



While we believe that our products and technology
do not infringe proprietary rights of others, third parties may assert infringement claims in the future and such claims could
be successful. Even if challenges are unsuccessful, we could incur substantial costs in defending ourselves against patent infringement
claims brought by others or in prosecuting suits against others. In addition, others may obtain patents that we would need to license,
which may not be available to us on reasonable terms. Whether we are able to obtain a necessary license would depend on the terms
offered, the degree of risk of infringement and the need for the patent.



If product liability, clinical trial liability or environmental
liability claims are brought against us or we are unable to obtain or maintain product liability, clinical trial or environmental
liability insurance, we may incur substantial liabilities that could reduce our financial resources.



The clinical testing and commercial use of pharmaceutical
products involves significant exposure to product liability, clinical trial liability, environmental liability and other risks
that are inherent in the testing, manufacturing and marketing of our products. These liabilities, if realized, could have a material
adverse effect on the Company’s business, results of operations and financial condition.



We have obtained limited product liability insurance
coverage for our clinical trials on humans; however, our insurance coverage may be insufficient to protect us against all product
liability damages. Regardless of merit or eventual outcome, liability claims may result in decreased demand for a future product,
injury to reputation, withdrawal of clinical trial volunteers, loss of revenue, costs of litigation, distraction of management
and substantial monetary awards to plaintiffs. Additionally, if we are required to pay a product liability claim, we may not have
sufficient financial resources to complete development or commercialization of any of our product candidates and our business and
results of operations will be adversely affected. In general, insurance will not protect us against some of our own actions, such
as negligence.



As the Company’s development activities
progress towards the commercialization of product candidates, our liability coverage may not be adequate, and the Company may not
be able to obtain adequate product liability insurance coverage at a reasonable cost, if at all. Even if the Company obtains product
liability insurance, its financial position may be materially adversely affected by a product liability claim. A product liability
claim could also significantly harm the Company’s reputation and delay market acceptance of its product candidates. Additionally,
product recalls may be issued at the direction of the FDA, other government agencies or other companies having regulatory control
for pharmaceutical sales. If a product recall occurs in the future, such a recall could adversely affect our business, financial
condition or reputation.



We may be unable to obtain partnerships for our product candidates,
which could curtail future development and negatively affect our share price. In addition, our partners might not satisfy their
contractual responsibilities or devote sufficient resources to our partnership.



Our strategy for the research, development and
commercialization of our products requires entering into various arrangements with corporate collaborators, licensors, licensees
and others, and our commercial success is dependent upon these outside parties performing their respective contractual responsibilities.
The amount and timing of resources that such third parties will devote to these activities may not be within our control. These
third parties may not perform their obligations as expected and our collaborators may not devote adequate resources to our programs.
In addition, we could become involved in disputes with our collaborators, which could result in a delay or termination of the related
development programs or result in litigation. We intend to seek additional collaborative arrangements to develop and commercialize
some of our products. We may not be able to negotiate collaborative arrangements on favourable terms, or at all, in the future,
and our current or future collaborative arrangements may not be successful.



If we cannot negotiate collaboration, license
or partnering agreements, we may never achieve profitability and we may not be able to continue to develop our product candidates.
Phase II and Phase III clinical trials for APTO-253 would require significant amounts of funding and such funding may not be available
to us.



Exchange rate risk



We are exposed to fluctuations of the Canadian
dollar against certain other currencies because we publish our financial statements and hold most of our investments in Canadian
dollars, while we incur many of our expenses in foreign currencies, primarily the United States dollar. Fluctuations in the value
of currencies such as the recent depreciation of the Canadian dollar against the United States dollar could cause us to incur currency
exchange losses. We do not currently employ a hedging strategy against exchange rate risk. We cannot assert with any assurance
that we will not suffer losses as a result of unfavorable fluctuations in the exchange rates between the Canadian dollar, the United
States dollar and other currencies.





22




Extensive Government Regulation



Government regulation is a significant factor
in the development, production and marketing of the Company’s products. Research and development, testing, manufacture, marketing
and sales of pharmaceutical products or related products are subject to extensive regulatory oversight, often in multiple jurisdictions,
which may cause significant additional costs and/or delays in bringing products to market, and in turn, may cause significant losses
to investors. The regulations applicable to the Company's product candidates may change. Even if granted, regulatory approvals
may include significant limitations on the uses for which products can be marketed or may be conditioned on the conduct of post-marketing
surveillance studies. Failure to comply with applicable regulatory requirements can, among other things, result in warning letters,
the imposition of civil penalties or other monetary payments, delay in approving or refusal to approve a product candidate, suspension
or withdrawal of regulatory approval, product recall or seizure, operating restrictions, interruptions of clinical trials or manufacturing,
injunctions or criminal prosecution. In addition, regulatory agencies many not approve the labeling claims that are necessary or
desirable for the successful commercialization of the Company’s product candidates.



Requirements for regulatory approval vary widely
from country to country. Whether or not approved in Canada or the United States, regulatory authorities in other countries must
approve a product prior to the commencement of marketing the product in those countries. The time required to obtain any such approval
may be longer or shorter than in Canada or the United States. Approved drugs, as well as their manufacturers, are subject to continuing
and ongoing review, and discovery of problems with these products or the failure to adhere to manufacturing or quality control
requirements may result in regulatory restrictions being imposed.



Risks Related to Our Common Shares



Our share price has been and is likely
to continue to be volatile and an investment in our Common Shares could suffer a decline in value.



You should consider an investment in our Common
Shares as risky and invest only if you can withstand a significant loss and wide fluctuations in the market value of your investment.
The market price of our Common Shares has been highly volatile and is likely to continue to be volatile. This leads to a heightened
risk of securities litigation pertaining to such volatility. Factors affecting our Common Share price include but are not limited
to:



|· |  | our ability to raise additional capital;
|- |  | ----------------------------------------



|· |  | the progress of our clinical trials:
|- |  | ------------------------------------



|· |  | our ability to obtain partners and collaborators to
assist with the future development of our products;
|- |  | -------------------------------------------------------------------------------------------------------



|· |  | general market conditions;
|- |  | --------------------------



|· |  | announcements of technological innovations or new product candidates by us, our collaborators
or our competitors;
|- |  | -----------------------------------------------------------------------------------------------------------------

|· |  | published reports by securities analysts;
|- |  | -----------------------------------------

|· |  | developments in patent or other intellectual property rights;
|- |  | -------------------------------------------------------------

|· |  | the cash and investments held by us and our ability to secure future financing;
|- |  | -------------------------------------------------------------------------------

|· |  | public concern as to the safety and efficacy of drugs that we and our competitors
develop;
|- |  | ------------------------------------------------------------------------------------------

|· |  | shareholder interest in our Common Shares; and
|- |  | ----------------------------------------------

|· |  | low liquidity in the daily trading volume of our Common Shares.
|- |  | ---------------------------------------------------------------



Future sales of our Common Shares by us
or by our existing shareholders could cause our share price to fall.



The issuance of Common Shares by us could result
in significant dilution in the equity interest of existing shareholders and adversely affect the market price of our Common Shares.
Sales by existing shareholders of a large number of our Common Shares in the public market and the issuance of shares issued in
connection with strategic alliances, or the perception that such additional sales could occur, could cause the market price of
our Common Shares to decline and have an undesirable impact on our ability to raise capital.



We are susceptible to stress in the global
economy and therefore, our business may be affected by the current and future global financial condition.



If the increased level of volatility and market
turmoil that have marked recent years continue, our operations, business, financial condition and the trading price of our Common
Shares could be materially adversely affected. Furthermore, general economic conditions may have a great impact on us, including
our ability to raise capital, our commercialization opportunities and our ability to establish and maintain arrangements with others
for research, manufacturing, product development and sales.





23




An active trading market in our Common
Shares may not be sustained.



Our Common Shares are listed for trading on
the NASDAQ Capital Market (“NASDAQ”) and the Toronto Stock Exchange (“TSX”). However, an
active trading market in our Common Shares on the stock exchanges may not be sustained and we may not be able to maintain our listings.



It may be difficult for non-Canadian investors
to obtain and enforce judgments against us because of our Canadian incorporation and presence.



We are a corporation existing under the laws
of Canada. Some of our directors and officers, and many of the experts named in this Annual Report and the documents incorporated
by reference into this Annual Report, are residents of Canada, and all or a substantial portion of their assets, and a substantial
portion of our assets, are located outside the United States. Consequently, although we have appointed an agent for service of
process in the United States, it may be difficult for holders of our shares who reside in the United States to effect service within
the United States upon our directors and officers and experts who are not residents of the United States. It may also be difficult
for holders of our shares who reside in the United States to realize in the United States upon judgments of courts of the United
States predicated upon our civil liability and the civil liability of our directors, officers and experts under the United States
federal securities laws. Investors should not assume that Canadian courts (i) would enforce judgments of United States courts obtained
in actions against us or our directors, officers or experts predicated upon the civil liability provisions of the United States
federal securities laws or the securities or “blue sky” laws of any state within the United States or (ii) would enforce,
in original actions, liabilities against us or our directors, officers or experts predicated upon the United States federal securities
laws or any such state securities or “blue sky” laws. In addition, we have been advised by our Canadian counsel that
in normal circumstances, only civil judgments and not other rights arising from United States securities legislation are enforceable
in Canada and that the protections afforded by Canadian securities laws may not be available to investors in the United States.



We are likely a “passive foreign
investment company” which may have adverse U.S. federal income tax consequences for U.S. shareholders.



U.S. investors in
our Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (“PFIC”)
during the tax year ended December 31, 2015, and based on the nature of our business, the projected composition of our gross income
and the projected composition and estimated fair market value of our assets, the Company expects to be a PFIC for the current
tax year ending December 31, 2016 and may be a PFIC in subsequent tax years. If the Company is a PFIC for any year during a U.S.
shareholder’s holding period, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition
of Common Shares, or any so-called “excess distribution” received on its Common Shares, as ordinary income, and to
pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely and effective “qualified
electing fund” election (“QEF election”) or a “mark-to-market” election with respect to the Common
Shares. A U.S. shareholder who makes a QEF election generally must report on a current basis its share of the Company’s
net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any
amounts to its shareholders. However, U.S. shareholders should be aware that we do not intend to satisfy record keeping requirements
that apply to a qualified electing fund, and we do not intend to supply U.S. shareholders with information that such U.S. shareholders
require to report under the QEF election rules, in the event that we are a PFIC and a U.S. shareholder wishes to make a QEF election.
Thus, U.S. shareholders should assume that they will not be able to make a QEF election with respect to their Common Shares. A
U.S. shareholder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair
market value of the Common Shares over the taxpayer’s basis therein. This paragraph is qualified in its entirety by the
discussion below under the heading “Certain United States Federal Income Tax Considerations.” Each U.S. shareholder
should consult its own tax advisor regarding the U.S. federal, U.S. local, and foreign tax consequences of the PFIC rules and
the acquisition, ownership, and disposition of our Common Shares.



We are an “emerging growth company,”
and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common shares
less attractive to investors.



We are an “emerging
growth company,” as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue
to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to
other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in
our periodic reports and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved.



We will cease to be
an emerging growth company upon the earliest of:



| | • | the
last day of the fiscal year during which we have total annual gross revenues of $1,000,000,000 (as such amount is indexed for
inflation every five years by the SEC or more;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



24






| | • | the
last day of our fiscal year following the fifth anniversary of the completion of our first sale of common equity securities pursuant
to an effective registration statement under the Securities Act;
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | • | the
date on which we have, during the previous three-year period, issued more than $1,000,000,000 in non- convertible debt; or
| | - | ------------------------------------------------------------------------------------------------------------------------------



| | • | the
date on which we are deemed to be a “large accelerated filer”, as defined in Rule 12b–2 of the Exchange Act,
which would occur if the market value of our ordinary shares and ADSs that are held by non-affiliates exceeds $700,000,000 as
of the last day of our most recently-completed second fiscal quarter.
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We cannot predict if
investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our Common
Shares less attractive as a result, there may be a less active trading market for our Common Shares and our share price may be
more volatile.



Any failure to maintain an effective
system of internal controls may result in material misstatements of our consolidated financial statements or cause us to fail to
meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders could lose confidence in our financial
reporting, which would harm our business and could negatively impact the price of our common shares.



Section 404(a) of the
Sarbanes-Oxley Act of 2002, as amended, or SOX, requires that our management assess and report annually on the effectiveness of
our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting.
Although Section 404(b) of the SOX requires our independent registered public accounting firm to issue an annual report that addresses
the effectiveness of our internal controls over financial reporting, we have opted to rely on the exemptions provided to us by
virtue of being a foreign private issuer and an emerging growth company, and consequently will not be required to comply with SEC
rules that implement Section 404(b) of SOX until we lose our emerging growth company status.



Effective internal
controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective system
of internal controls, we might not be able to report our financial results accurately or prevent fraud; and in that case, our shareholders
could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our common
shares. While we believe that we have sufficient personnel and review procedures to allow us to maintain an effective system of
internal controls, we cannot assure you that we will not experience potential material weaknesses in our internal control. Even
if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial
reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS, as issued by
the International Accounting Standards Board, because of its inherent limitations, internal control over financial reporting may
not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered
in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations.



If we fail to timely
achieve and maintain the adequacy of our internal control over financial reporting, we may not be able to produce reliable financial
reports or help prevent fraud. Our failure to achieve and maintain effective internal control over financial reporting could prevent
us from complying with our reporting obligations on a timely basis, which could result in the loss of investor confidence in the
reliability of our consolidated financial statements, harm our business and negatively impact the trading price of our common shares.



As a foreign private issuer, we are
not subject to certain United States securities law disclosure requirements that apply to a domestic United States issuer, which
may limit the information which would be publicly available to our shareholders.



As a foreign private
issuer, we are exempt from certain rules under the Exchange Act that impose disclosure requirements as well as procedural requirements
for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders
are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act. Moreover,
we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as a company that
files as a domestic issuer whose securities are registered under the Exchange Act, nor are we generally required to comply with
the SEC’s Regulation FD, which restricts the selective disclosure of material non-public information. For as long as we
are a “foreign private issuer” we intend to file our annual financial statements on Form 20-F and furnish our quarterly
updates on Form 6-K to the SEC for so long as we are subject to the reporting requirements of Section 13(g) or 15(d) of the Exchange
Act. However, the information we file or furnish is not the same as the information that is required in annual and quarterly reports
on Form 10-K or Form 10-Q for U.S. domestic issuers. Accordingly, there may be less information publicly available concerning
us than there is for a company that files as a domestic issuer.





25




DISCLOSURE
CONTROLS AND INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company has implemented a system of internal
controls that it believes adequately protects the assets of the Company and is appropriate for the nature of its business and the
size of its operations. Our internal control system was designed to provide reasonable assurance that all transactions are accurately
recorded, that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and
that our assets are safeguarded. These internal controls include disclosure controls and procedures designed to ensure that information
required to be disclosed by the Company is accumulated and communicated as appropriate to allow timely decisions regarding required
disclosure.



Internal
control over financial reporting means a process designed by or under the supervision of the Chief Executive Officer and the Chief
Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with IFRS as issued by the IASB. The internal controls are not expected to prevent
and detect all misstatements due to error or fraud.



There were no changes in our internal control over financial reporting
that occurred during the year ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting



As of December 31, 2016, the Company’s management has assessed
the effectiveness of our internal control over financial reporting and disclosure controls and procedures using the Committee
of Sponsoring Organizations of the Treadway Commission’s 2013 framework. Based on their evaluation, the Chief Executive
Officer and the Chief Financial Officer have concluded that these controls and procedures are effective.



UPDATED
SHARE INFORMATION



As at March 28, 2017, we had 18,849,224 common shares issued and
outstanding. In addition there were 1,970,587 common shares issuable upon the exercise of outstanding stock options.



ADDITIONAL
INFORMATION



Additional information relating
to Aptose, including Aptose' December 31, 2016 annual report on form 20-F and other disclosure documents, are available on EDGAR
atwww.sec.gov/edgar.shtml and on SEDAR atwww.sedar.com.











26